A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Status:
Completed

Trial end date:
2019-12-10

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).

Phase 2

Vertex Pharmaceuticals Incorporated

Ivacaftor